CluePoints’ Launch of Post-COVID Trial Assurance Solution
CluePoints has launched a new Post-COVID Trial Assurance Solution as part of its mission to build safer, more efficient trials for patients, sponsors and CROs.
The new CluePoints Post-COVID Trial Assurance Solution offers study teams the opportunity to assess the quality of their data within a defined timeline and with limited resources. It goes beyond traditional key risk indicators to evaluate 100% of the clinical data to assess expected risks, while also identifying data anomalies which might indicate unexpected risks—surfacing issues which can be found by leveraging CluePoints’ Central Statistical Monitoring Platform.
Furthermore, CluePoints can provide Data Scientists to do all the heavy lifting and work with the study team to support plans to identify and resolve issues and document what’s been done to mitigate the risks.
The Post-COVID Trial Assurance Solution includes (subject to expert consultation as to what will work best on your specific study or studies):
- Comprehensive Central Statistical Analysis
The comprehensive statistical analysis provides a complete unsupervised analysis of all clinical data to uncover unknown risks in your trial
- Key Risk Indicators (KRIs)
The Key Risk Indicator module provides a convenient way to monitor how sites are performing versus the metrics that are important to the trial
- Patient Profiles
By coupling Patient Profiles with Central Statistical Monitoring, patients can be ranked by their relative degree of atypicality, allowing clinical teams to get the patients that need it reviewed faster
- Duplicate Patients
If the existence of ‘Professional Patients’ participating in the trial is a concern, CluePoints’ Duplicate Patients module can identify them so that any sign of enrolment abuse can be investigated and addressed
For more information, click here.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
